Diabetic periodontitis: A model for activated innate immunity and impaired resolution of inflammation

Periodontology 2000

Volumn 43, Issue 1, 2007, Pages 233-244

  Nassar, Hamdy ^a   Kantarci, Alpdogan ^a   Van Dyke, Thomas E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AUTACOID; DIACYLGLYCEROL; PROTEIN KINASE C;

ANIMAL; DIABETES MELLITUS; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; OXIDATIVE STRESS; PERIODONTITIS; REVIEW;

ANIMALS; DIABETES COMPLICATIONS; DIGLYCERIDES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNITY, NATURAL; INFLAMMATION MEDIATORS; OXIDATIVE STRESS; PERIODONTITIS; PROTEIN KINASE C;

EID: 33846109538     PISSN: 09066713     EISSN: 16000757     Source Type: Journal    
DOI: 10.1111/j.1600-0757.2006.00168.x     Document Type: Review

References (125)

1. Abordo EA, Westwood ME, Thornalley PJ. Synthesis and secretion of macrophage colony stimulating factor by mature human monocytes and human monocytic THP-1 cells induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced glycation end products. Immunol Lett 1996: 53: 7-13.
2. Babior BM. NADPH oxidase: an update. Blood 1999: 93: 1464-1476.
3. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991: 40: 405-412.
4. Bouin AP, Grandvaux N, Vignais PV, Fuchs A. p40(phox) Is phosphorylated on threonine 154 and serine 315 during activation of the phagocyte NADPH oxidase. Implication of a protein kinase c-type kinase in the phosphorylation process. J Biol Chem 1998: 273: 30097-30103.
5. Boulton AJM. Pathogenesis of diabetic neuropathy. In: Marshall SM, Home PD, Alberti KG, Krall LP, eds. The Diabetes Annual 7. Amsterdam: Elsevier, 1993: 192-210.
6. Bower G, Brown DM, Steffes MW, Vernier RL, Mauer SM. Studies of the glomerular mesangium and the juxtaglomerular apparatus in the genetically diabetic mouse. Lab Invest 1980: 43: 333-341.
7. Brady HR, Serhan CN. Lipoxins: putative braking signals in host defense, inflammation and hypersensitivity. Curr Opin Nephrol Hypertens 1996: 5: 20-27.
8. Bragger U, Muhle T, Formousis I, Lang NP, Mombelli A. Effect of the NSAID flurbiprophen on remodeling after periodontal surgery. J Periodontal Res 1997: 32: 575-582.
9. Bridges RB, Anderson JW, Sax SR, Gregory K, Bridges SR. Periodontal status of diabetic and non-diabetic men: effect of smoking, glycemic control, and socioeconomic factors. J Periodontol 1996: 67: 1158-1192.
10. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001: 414: 813-820.
11. Ceriello A. Oxidative stress and glycemic regulation. Metabolism 2000: 49: 27-29.
12. Charonis AS Reger LA, Dege JE, Kouzi-Koliakos K, Furcht LT, Wohlhueter RM, Tsilibary EC. Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes 1990: 39: 807-814.
13. Claria J, Lee MH, Serhan CN. Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Mol Med 1996: 2: 583-596.
14. Craven PA, Studer RK, DeRubertis FR. Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats. Evidence for protein kinase C-mediated suppression of the cholinergic response. J Clin Invest 1994: 93: 311-320.
15. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ. Receptor specific increase in extracellular matrix productions in mouse mesangial cells by advanced glycosylation end products is mediated via platelet derived growth factor. Proc Natl Acad Sci U S A 1992: 89: 2873-2877.
16. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 2000: 97: 12222-12226.
17. Elner S, Elner V, Jaffe G, Stuart A, Kunkel S, Strieter R. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res 1995: 14: 1045-1053.
18. Engerman RL, Kern TS, Larson ME. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs. Diabetologia 1994: 37: 141-144.
19. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002: 23: 599-622.
20. Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, Faggioni R, Fantuzzi G, Ghezzi P, Poli V. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 1994: 180: 1243-1250.
21. Fernandez-Real J, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, Ricart W. Circulating interleukin-6 levels, blood pressure and insulin resistance in apparently healthy men and women. J Clin Endocrinol Metab 2001: 86: 1154-1159.
22. Fiala E, Westendorf J, West IC. Radicals and oxidative stress in diabetes. Toxicology 2000: 146: 83-92.
23. Frank RN. Diabetic retinopathy. Prog Ret Eye Res 1995: 14: 361-392.
24. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999: 340: 448-454.
25. Gabbay KH. Hyperglycemia, polyol metabolism, and complications of diabetes mellitus. Ann Rev Med 1975: 26: 521-536.
26. Ganz MB, Seftel A. Glucose-induced changes in protein kinase C and nitric oxide are prevented by vitamin E. Am J Physiol 2000: 278: E1460-E152.
27. Geerlings S, Brouwer E, Van Kessel K, Gaastra W, Stolk R, Hoepelman A. Cytokine secretion is impaired in women with diabetes mellitus. Eur J Clin Invest 2000: 30: 995-1001.
28. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996: 19: 257-267.
29. Glogowski EA, Tsiani E, Zhou X, Fantus IG, Whiteside C. High glucose alters the response of mesangial cell protein kinase C isoforms to endothelin-1. Kidney Int 1999: 55: 486-499.
30. Golub LM, Sorsa T, Lee H-M, Ciancio S, Sorbi D, Ramamurthy NS, Gruber B, Salo T, Konttinen YT. Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinase in human adult periodontitis gingiva. J Clin Periodontol 1995: 22: 100-109.
31. Goova MT, Li J, Kislinger T, Qu W, Bucciarelli LG, Nowygrod S Wolf BM, Caliste X, Yan SF, Stern DM, Schmidt AM. Blockade of receptors for advanced glycation endproducts restores effective wound healing in diabetic mice. Am J Pathol 2001: 159: 513-525.
32. Graves DT, Oskoui M, Volejnikova S, Naguib G, Cai S, Desta T, Kakouras A, Jiang Y. Tumor necrosis factor modulates fibroblast apoptosis, PMN recruitment, and osteoclast formation in response to P. gingivalis infection. J Dent Res 2001: 80: 1875-1879.
33. Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 1999: 53: 580-591.
34. Grossi SG, Genco RJ. Periodontal disease and diabetes mellitus: a two-way relationship. Ann Periodontol 1998: 3: 51-61.
35. Grossi SG, Skrepcinski FB, DeCaro T, Robertson DC, Ho AW, Dunford RG, Genco RJ. Treatment of periodontal disease in diabetics reduces glycated hemoglobin. J Periodontol 1997: 68: 713-719.
36. Guha M, Bai W, Nadler J, Natarajan R. Molecular mechanisms of TNF-alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress dependent and independent pathways. J Biol Chem 2000: 275: 17728-17739.
37. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, Channon KM. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Cir Res 2000: 86: E85-E90.
38. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A 1991: 88: 11555-11559.
39. Hart GW. Dynamic O-linked glycosylation of nuclear and cytoskeletal proteins. Annu Rev Biochem 1997: 66: 315-335.
40. Heitzer T, Wenzel U, Hink U, Krollner D, Skatchkov M, Stahl RA, MacHarzina R, Brasen JH, Meinertz T, Munzel T. Increased NAD(P)H oxidase-mediated superoxide production in renovascular hypertension: evidence for an involvement of protein kinase C. Kidney Int 1999: 55: 252-260.
41. Hempel A, Maasch C, Heintze U, Lindschau C, Dietz R, Luft FC, Haller H. High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha. Circ Res 1997: 81: 363-371.
42. Idris I, Gray S, Donnelly R. Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia 2001: 44: 659-673.
43. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, Hashimoto T, Naruse M, Sano H, Utsumi H, Nawata H. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000: 49: 1939-1945.
44. Inoguchi T, Sonta T, Tsubouchi H, Etoh T, Kakimoto M, Sonoda N, Sato N, Sekiguchi N, Kobayashi K, Sumimoto H, Utsumi H, Nawata H. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 2003: 14: S227-S232.
45. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996: 272: 728-731.
46. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study. Diabetes 2000: 49: 485-491.
47. Jones SA, O'Donnell VB, Wood JD, Broughton JP, Hughes EJ, Jones OT. Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol Heart Circ Physiol 1996: 271: H1626-H1634.
48. Karima M, Kantarci A, Ohira T, Hasturk H, Jones VL, Nam B-H, Malabanan A, Trackman PC, Badwey JA, Van Dyke TE. Enhanced superoxide release and elevated protein Kinase C activity in neutrophil from diabetic patients: association with periodontitis. J Leukocyte Biol 2005: 78: 1-9.
49. Kashiwagi A, Shinozaki K, Nishio Y, Maegawa H, Maeno Y, Kanazawa A, Kojima H, Haneda M, Hidaka H, Yasuda H, Kikkawa R. Endothelium-specific activation of NAD(P)H oxidase in aortas of exogenously hyperinsulinemic rats. Am J Physiol Endocrinol Metab 1999: 277: E976-E983.
50. Keogh RJ, Dunlop ME, Larkins RG. Effect of inhibition of aldose reductase on glucose flux, diacylglycerol formation, protein kinase C, and phospholipase A2 activation. Metabolism 1997: 46: 41-47.
51. Kirstein M, Aston C, Hintz R, Vlassara H. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 1992: 90: 439-446.
52. Kitada M, Koya D, Sugimoto T, Isono M, Araki S, Kashiwagi A, Haneda M, Translocation of glomerular p47phox and p67phox by protein kinase C activation is required for oxidative stress in diabetic nephropathy. Diabetes 2003: 52: 2603-2614.
53. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998: 47: 859-866.
54. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, Sugimoto T, Yasuda H, Kashiwagi A, Ways DK, King GL, Kikkawa R. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000: 14: 439-447.
55. 2 generation in human adipocyte plasma membranes is mediated by Galphai2. J Biol Chem 1997: 272: 10135-10143.
56. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, Feener EP, Herbert TP, Rhodes CJ, King GL. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo a specific vascular action of insulin. Circulation 2000: 101: 676-681.
57. Kumar V, Abbas AK, Fausto N, Kumar V, Abbas AK, Fausto N (editors). Robbins and Cotran Pathologic Basis of Disease, 7th edn. Philadelphia, PA: Elsevier Saunders, 2005: 47-86.
58. Kuroki T, Isshiki K, King GL. Oxidative stress: the lead or supporting actor in the pathogenesis of diabetic complications. J Am Soc Nephrol 2003: 14: S216-S220.
59. Lalla E Lamster IB, Feit M, Huang L, Spessot A, Qu W, Kislinger T, Lu Y, Stern DM, Schmidt AM. Blockade of RAGE suppresses periodontitis-associated alveolar bone loss in diabetic mice. J Clin Invest 2000: 105: 1117-1124.
60. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997: 272: 17810-17814.
61. Li YM, Mitsuhashi T, Wojciechowicz D, Shimizu N, Li J, Stitt A, He C, Banerjee D, Vlassara H. Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90-80KH membrane proteins. Proc Natl Acad Sci U S A 1996: 93: 11047-11052.
62. Liljenberg B, Lindhe J, Berglundh T, Dahlen G, Jonsson R. Some microbiological, histopathological and immunohistochemical characteristics of progressive periodontal disease. J Clin Periodontol 1994: 21: 720-727.
63. Loots MA, Lamme EN, Zeegelaar J, Mekkes JR, Bos JD, Middelkoop E. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J Invest Dermatol 1998: 111: 850-857.
64. Lusis AJ. Atherosclerosis. Nature 2000: 407: 233-241.
65. Mahadev K, Wu X, Zilbering A, Zhu L, Lawrence JT, Goldstein BJ. Hydrogen peroxide generated during cellular insulin stimulation is integral to activation of the distal insulin signaling cascade in 3T3-L1 adipocytes. J Biol Chem 2001: 276: 48662-48669.
66. Mahadev K, Zilbering A, Zhu L, Goldstein BJ. Insulin-stimulated hydrogen peroxide reversibly inhibits protein-tyrosine phosphatase 1b in vivo and enhances the early insulin action cascade. J Biol Chem 2001: 276: 21938-21942.
67. 2 and plays an integral role in insulin signal transduction. Mol Cell Biol 2004: 24: 1844-1854.
68. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 2001: 108: 635-636.
69. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001: 1: 135-145.
70. Medzhitov R, Janeway CA. Decoding the patterns of self and nonself by the innate immune system. Science 2002: 296: 298-300.
71. Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W, Yanagisawa K, Kawata T, Koike T. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997: 46: 895-899.
72. Nathan C. Points of control in inflammation. Nature 2002: 420: 846-852.
73. Nelson RG, Shlossman M, Budding LM, Pettitt DJ, Saad MF, Genco RJ, Knowler WC. Periodontal disease and NIDDM in Pima Indians. Diabetes Care 1998: 13: 836-840.
74. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 2000: 404: 787-790.
75. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000: 404: 787-790.
76. Oates PJ. Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol 2002: 50: 325-392.
77. Offenbacher S. Periodontal diseases: pathogenesis. Ann Periodontol 1996: 1: 821-878.
78. Offenbacher S, Odle BM, Gray RC, Van Dyke TE. Crevicular fluid prostaglandin E levels as a measure of the periodontal disease status of adult and juvenile periodontitis patients. J Periodontal Res 1984: 19: 1-13.
79. 2 levels as a predictor of periodontal attachment loss. J Periodontal Res 1986: 21: 101-112.
80. Okumura M, Okuda T, Nakamura T, Yajima M. Acceleration of wound healing in diabetic mice by basic fibroblast growth factor. Biol Pharm Bull 1996: 19: 530-535.
81. 2-microglobulin modified with advanced glycation endproducts modulates collagen synthesis by human fibroblasts. Kidney Int 1998: 53: 1365-1371.
82. 1 down-regulates inflammatory cytokine-induced VCAM-1 expression in cultured human glomerular endothelial cells. Nephrol Dial Transplant 2000: 15: 596-604.
83. Peppa M, Brem H, Ehrlich P, Zhang JG, Cai W, Li Z, Croitoru A, Thung S, Vlassara H. Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes 2003: 52: 2805-2813.
84. Pickup JC, Crook M. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998: 41: 1241-1248.
85. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997: 40: 1286-1292.
86. Pickup JC, Chusney GC, Thomas SM, Burt D. Plasma interleukin-6, tumor necrosis factor alpha and blood cytokine production in types 2 diabetes. Life Sci 2000: 67: 291-300.
87. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. Creactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001: 286: 327-334.
88. Quyyumi AA. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 1998: 105: 32S-39S.
89. Rodriguez-Manas L, Angulo J, Vallejo S, Peiro C, Sanchez-Ferrer A, Cercas E, Lopez-Doriga P, Sanchez-Ferrer CF. Early and intermediate Amadori glycosylation adducts, oxidative stress, and endothelial dysfunction in the streptozotocin-induced diabetic rats vasculature. Diabetologia 2003: 46: 556-566.
90. Ross AD, Sheng H, Warner DS, Piantadosi CA, Batinic-Haberle I, Day BJ, Crapo JD. Hemodynamic effects of metalloporphyrin catalytic antioxidants: structure-activity relationships and species specificity. Free Radic Bio Med 2002: 33: 1657-1669.
91. Santana RB, Xu L, Chase HB, Amar S, Graves DT, Trackman PC. A role for advanced glycation endproducts in diminished bone healing in type 1 diabetes. Diabetes 2003: 52: 1502-1510.
92. Sartippour MR, Renier G. Upregulation of macrophage lipoprotein lipase in patients with type 2 diabetes: role of peripheral factors. Diabetes 2000: 49: 597-602.
93. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991: 88: 2095-2105.
94. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995: 96: 1395-1403.
95. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracey RP, Heiss G. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999: 353: 1649-1652.
96. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001: 108: 949-955.
97. Serhan CN. Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim Biophys Acta 1994: 1212: 1-25.
98. Serhan CN. Eicosanoids in leukocyte function. Curr Opin Hematol 1994: 1: 69-77.
99. Serhan CN, Fiore S. Lipoxin recognition sites of human neutrophils. Adv Prostaglandin Thromboxane Leukotriene Res 1994: 22: 317-326.
100. Serhan CN, Oliw E. Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways. J Clin Invest 2001: 107: 1481-1489.
101. Serhan CN, Fiore S, Levy BD. Cell-cell interactions in lipoxin generation and characterization of lipoxin A4 receptors. Ann NY Acad Sci 1994: 744: 166-180.
102. Serhan CN, Maddox JF, Petasis N, Papayianni A, Brady HR, Colgan SP, Madara J. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 1995: 34: 14609-14615.
103. Serhan CN, Haeggstrom JZ, Leslie CC. Lipid mediator networks in cell signaling: update and impact of cytokine. FASEB J 1996: 10: 1147-1158.
104. Serhan CN, Jain A, Marleau S, Clish C, Kantarci A, Behbehani B, Colgan SP, Stahl GL, Merched A, Petasis NA, Chan L, Van Dyke TE. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol 2003: 171: 6856-6865.
105. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002: 288: 2579-2588.
106. Shlossman M, Knowler WC, Pettitt DJ, Genco RJ. Type 2 diabetes mellitus and periodontal disease. J Am Dent Assoc 1990: 121: 532-536.
107. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodeling and diabetic nephropathy. J Exp Med 1991: 174: 931-939.
108. Socransky SS, Haffajee AD. The bacterial etiology of destructive periodontal disease: current concepts. J Periodontol 1992: 63: 322-331.
109. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991: 40: 1328-1334.
110. Spranger J, Kroke A, Möhlig M, Hoffman K, Bergman MM, Ristow M, Boeing H, Pfeiffer AF. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. Diabetes 2003: 52: 812-817.
111. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 (UKPDS 35): prospective observational study. BMJ 2000: 321: 405-412.
112. Tanaka S, Avigad G, Brodsky B, Eikenberry EF. Glycation induces expansion of the molecular packing of collagen. J Mol Biol 1988: 203: 495-505.
113. Taylor GW, Burt BA, Becker MP, Genco RJ, Shlossman M, Knowler WC, Pettitt DJ. Severe periodontitis and risk for poor glycemic control in patients with non-insulin-dependent diabetes mellitus. J Periodontol 1996: 67: 1085-1093.
114. Taylor GW, Burt BA, Becker MP, Genco RJ, Shlossman M, Knowler WC, Pettitt DJ. Non-insulin dependent diabetes mellitus and alveolar bone loss progression over 2 years. J Periodontol 1998: 69: 76-83.
115. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 977-986.
116. Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 2003: 25: 275-281.
117. 4 in the gingival crevicular fluid. J Dent 1998: 26: 97-103.
118. Tsai C, Hayes C, Taylor GW. Glycemic control of type 2 diabetes and severe periodontal disease in the US adult population. Commun Dent Oral Epidemiol 2002: 30: 182-192.
119. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998: 352: 837-853.
120. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998: 352: 854-865.
121. Van Dyke TE, Lester MA, Shapira L. The role of the host response in periodontal disease progression: implication for future treatment strategies. J Periodontol 1993: 64: 792-806.
122. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988: 240: 1546-1548.
123. Williams B, Gallacher B, Patel H, Orme C. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997: 46: 1497-1503.
124. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994: 269: 9889-9897.
125. Zykova S, Jenssen T, Berdal M, Olsen R, Myklebust R, Seljelid R. Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic type II-like db/db mice. Diabetes 2000: 49: 1451-1458.